GlassScriptPhysician profile
Vijay Chechani
NPI 1912960618
$2,245.87
in general payments reported to CMS, 2019-2025
16 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $283 · 2021: $651 · 2022: $495 · 2023: $229 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $669.20 | 2019-2025 | Fasenra, Breztri, Tagrisso |
| Glaxosmithkline, LLC. | $460.20 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Mylan Specialty L.P. | $381.01 | 2019-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.12 | 2019-2023 | Ofev |
| Jazz Pharmaceuticals INC. | $72.36 | 2019-2022 | |
| Philips North America LLC | $72.08 | 2019 | |
| Inspire Medical Systems, INC. | $63.74 | 2025 | Inspire |
| Pulmonx Corporation | $61.91 | 2022-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Harmony Biosciences LLC | $45.10 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $31.96 | 2019-2021 | |
| United Therapeutics Corporation | $23.54 | 2021 | |
| Gilead Sciences, INC. | $20.94 | 2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $20.70 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $18.61 | 2021 | |
| Merck Sharp & Dohme LLC | $15.66 | 2025 | Keytruda, Welireg |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Chechani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.